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Early and Late Posttransplant Lymphoproliferative Disorder After Lung
TransplantationV34 Cases From the European PTLD Network
Jaksch et al. (1) have recently reporteda low incidence of posttransplant lym-
phoproliferative disorder (PTLD) of B-
cell origin after lung transplantation (18
in a series of 1157 [1.6%] consecutive
patients) in Vienna. Their findings show
that posttransplantation management is
crucial to PTLD prevention and docu-
ment the effectiveness of the program
in Vienna. The authors hypothesize that
their use of anti-cytomegalovirus (CMV)
immunoglobulin prophylaxis (Cytotect,
1 mL/kg intravenously on days 1, 7, 14,
and 21 postoperatively) protects patients
from Epstein-Barr virus (EBV)Yassociated
PTLD. This hypothesis is based on the
findings by Opelz et al. (2) who had ob-
served no cases of PTLD within the first
year after transplantation in 2103 kidney
transplant recipients who had received
anti-CMV immunoglobulin prophylaxis
for 4 months after transplantationV
significantly less than in an untreated
control group. However, in the subse-
quent 5 years, new cases of PTLD devel-
oped at similar rates in the examined
groups with and without CMV prophylaxis.
We were intrigued by the low pro-
portion of late PTLD reported (only 3 of
18 cases occurred 91 year after transplan-
tation) and analyzed time-to-PTLD in
lung transplant recipients in the PTLD-1
(3) and PTLD 1Y3 (4) trials as well as those
treated at Hopital Pitie-Salpêtriere, Paris,
or reported to the German PTLD registry.
Overall, 34 patients with PTLD after lung
transplantation were included from cen-
ters in Australia, Austria, Belgium, France,
and Germany. Twenty-two of 34 had
received lung transplants and 12 of 34
had received combined heart/lung trans-
plants between 1988 and 2011. Strikingly,
in both groups, less than 40% of cases
occurred in the first year after trans-
plantation (early PTLD) (Table 1). We
observed cases later than 2 years (16 of
34 [47%]), 5 years (10 of 34 [29%]), and
10 years (6 of 34 [18%]). Furthermore,
6 of 31 patients with PTLD after lung or
heart/lung transplantation evaluated for
EBVassociation had EBV-negative disease
by EBV-encoded RNA in situ hybridiza-
tion. These included two cases of diffuse
large B-cell lymphoma (DLBCL)-PTLD
































Heart/lung 12 5 (42%) 2001 (1988Y2010) 1.30 0.28Y23.43 4/12 (33%) 9 DLBCL PTLD 8/10
1 PBL PTLD
2 unknown
a EBV data missing in three cases.
MZL, marginal zone lymphoma; PBL, plasmablastic lymphoma.
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and one case each of marginal-zone
PTLD, plasmacytoma-like PTLD, plasma-
blastic PTLD, and lymphoplasmocytic
PTLD (median time-to-PTLD, 7.6 years;
range, 3.8Y12.0 years).
In comparison with our cases and
the data of Opelz et al. (2), the key ob-
servation of Jaksch et al. (1) is the low
proportion of late (and EBV-negative)
PTLD in their transplant cohort. It is
therefore possible to speculate that this
effect was achieved not only through
early administration of CMV immuno-
globulin but by optimized immunosup-
pression throughout follow-up, potentially
aided by monitoring of CMV polymer-
ase chain reaction. A reduction of PTLD
incidence through viral load monitoring
(of EBV viral load) and immunosup-
pression alteration has previously been
demonstrated after heart (5) and pedi-
atric liver (6) transplantation. The test of
this hypothesis will be the future inci-
dence of late PTLD in the Vienna cohort.
We would like to note that the
differences between our cases and the
cohort presented by Jaksch et al. might
to some extent reflect selection bias
(patients referred to a hematologist for
treatment). Furthermore, we did not con-
trol for PTLD risk factors such as EBV
serostatus at transplantation.
Median overall survival of PTLD
after lung transplantation was 1.1 years
in the 18 patients reported by Jaksch
et al. (1). We observed a median sur-
vival of 1.2 years for both our entire
cohort of 34 patients and the subgroup
of 22 lung transplant recipients. In ad-
dition, the four lung transplant recip-
ients treated with sequential therapy
(rituximab and CHOP chemotherapy)
in the PTLD-1 trial (3) achieved a sim-
ilarly poor median overall survival of
only 1.0 years compared with a median
overall survival of 6.6 years for the en-
tire trial cohort of 70 patients with
PTLD. This reinforces the need for both
effective prophylaxis of and improved
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Charité-Universitätsmedizin Berlin
Campus Virchow-Klinikum
Berlin, Germany; for the German
PTLD Study Group and the European
PTLD Network.
The German and the French PTLD Study Groups
were supported by Roche, Amgen, and Chugai
to conduct the PTLD-1 trial with an unre-
stricted grant. The German PTLD D 2006Y2012
registry is supported by grants from Amgen,
CLS Behring, Mundipharma GmbH, and Roche
Pharma AG.
The authors declare no conflicts of interest.
Address correspondence to: PD Dr. med. Ralf
Ulrich Trappe, Department of Internal Medi-
cine II: Haematology and Oncology, University
Medical Center Schleswig-Holstein, Campus
Kiel, Haus 50, Arnold-Heller Strasse 3, 24105
Kiel, Germany.
E-mail: rtrappe@gwdg.de
Received 2 April 2013.
Accepted 8 May 2013.




1. Jaksch P, Wiedemann D, Kocher A, et al.
Effect of cytomegalovirus immunoglobulin
on the incidence of lymphoproliferative dis-
ease after lung transplantation: single-center
experience with 1157 patients. Transplanta-
tion 2013; 95: 766.
2. Opelz G, Daniel V, Naujokat C, et al. Effect
of cytomegalovirus prophylaxis with im-
munoglobulin or with antiviral drugs on
post-transplant non-Hodgkin lymphoma:
a multicentre retrospective analysis. Lancet
Oncol 2007; 8: 212.
3. Trappe R, Oertel S, Leblond V, et al. Se-
quential treatment with rituximab followed
by CHOP chemotherapy in adult B-cell
post-transplant lymphoproliferative disor-
der (PTLD): the prospective international
multicentre phase 2 PTLD-1 trial. Lancet
Oncol 2012; 13: 196.
4. Trappe RU, Dierickx D, Reinke P, et al. In-
terim analysis of the largest prospective trial
to date in adult CD20-positive post-transplant
lymphoproliferative disorder (PTLD): intro-
ducing risk-stratified sequential treatment
(RSST). ASCO Meet Abstr 2012; 30: 8030.
5. Choquet S, Varnous S, Deback C, et al.
Adapted management of EBV reactivation
after solid organ transplantation: an effective
prevention of post transplantation lympho-
proliferative disorders (PTLD). Results of the
largest prospective study on 251 patients.
ASH Annu Meet Abstr 2010; 116: 592.
6. Lee TC, Savoldo B, Rooney CM, et al.
Quantitative EBV viral loads and immu-
nosuppression alterations can decrease PTLD
incidence in pediatric liver transplant re-
cipients. Am J Transplant 2005; 5: 2222.
* 2013 Lippincott Williams & Wilkins Letters to the Editor e19
Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
